


## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32719A  
APPLICATION NO.  
10/530,451  
APPLICANT  
Frank Giles  
FILING DATE  
OCTOBER 4, 2005

Group

1611

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	90-35958*	0/20/90	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	00-59509*	10/12/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.J.T./	AR	Barosi G., "Myelofibrosis with Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines," Journal of Clinical Oncology, Vol. 17(9), pp. 2954-2970 (1999).
/M.J.T./	AS	Hasselbach H.C., "A possible Role for STI571 in the Treatment of Idiopathic Myelofibrosis," American Journal of Hematology, Vol. 68(1), pp. 63-64 (2001)*
/M.J.T./	AT	Lin et al., "The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment," Cancer Research, Vol. 62(17), pp. 5019-5026 (2002)*

EXAMINER /Michael J. Teale PhD/

DATE CONSIDERED 01/09/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
ON/4-32719A  
APPLICATION NO.  
10/530,451  
APPLICANT  
Frank Giles  
FILING DATE  
OCTOBER 4, 2005

Sheet 2 of 2

Group

16/11

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

/M.J.T./	BR	Tefferi et al., "Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia," Blood, Vol. 99(10), pp. 3854-3856 (2002).
	BS	
	BT	

EXAMINER

/Michael J. Teale PhD/

DATE CONSIDERED

01/09/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.